Nicola J Wiles

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4909224/publications.pdf

Version: 2024-02-01

85	3,947	29 h-index	59
papers	citations		g-index
91	91	91	5809
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Therapist-delivered internet psychotherapy for depression in primary care: a randomised controlled trial. Lancet, The, 2009, 374, 628-634.	13.7	340
2	Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet, The, 2013, 381, 375-384.	13.7	278
3	Self-reported psychotic symptoms in the general population. British Journal of Psychiatry, 2006, 188, 519-526.	2.8	214
4	Insomnia, worry, anxiety and depression as predictors of the occurrence and persistence of paranoid thinking. Social Psychiatry and Psychiatric Epidemiology, 2012, 47, 1195-1203.	3.1	190
5	Facilitated physical activity as a treatment for depressed adults: randomised controlled trial. BMJ, The, 2012, 344, e2758-e2758.	6.0	163
6	User Experience of Cognitive Behavioral Therapy Apps for Depression: An Analysis of App Functionality and User Reviews. Journal of Medical Internet Research, 2018, 20, e10120.	4.3	147
7	Validity of the Short Mood and Feelings Questionnaire in late adolescence Psychological Assessment, 2014, 26, 752-762.	1.5	137
8	Birth weight and psychological distress at age 45–51 years. British Journal of Psychiatry, 2005, 187, 21-28.	2.8	118
9	Prevalence of treatment-resistant depression in primary care: cross-sectional data. British Journal of General Practice, 2013, 63, e852-e858.	1.4	115
10	Early Parental and Child Predictors of Recurrent Abdominal Pain at School Age: Results of a Large Population-Based Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 729-736.	0.5	110
11	Is socioeconomic status in early life associated with drug use? A systematic review of the evidence. Drug and Alcohol Review, 2009, 28, 142-153.	2.1	110
12	Cost-effectiveness of therapist-delivered online cognitive–behavioural therapy for depression: randomised controlled trial. British Journal of Psychiatry, 2010, 197, 297-304.	2.8	103
13	Long-term effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: follow-up of the CoBalT randomised controlled trial. Lancet Psychiatry,the, 2016, 3, 137-144.	7.4	103
14	Fetal Growth and Childhood Behavioral Problems: Results from the ALSPAC Cohort. American Journal of Epidemiology, 2006, 163, 829-837.	3.4	95
15	Is screen time associated with anxiety or depression in young people? Results from a UK birth cohort. BMC Public Health, 2019, 19, 82.	2.9	81
16	The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial. Lancet Psychiatry,the, 2019, 6, 903-914.	7.4	78
17	Maintenance or Discontinuation of Antidepressants in Primary Care. New England Journal of Medicine, 2021, 385, 1257-1267.	27.0	7 5
18	Physical activity and emotional problems amongst adolescents. Social Psychiatry and Psychiatric Epidemiology, 2008, 43, 765-772.	3.1	74

#	Article	IF	CITATIONS
19	The process and delivery of CBT for depression in adults: a systematic review and network meta-analysis. Psychological Medicine, 2019, 49, 1937-1947.	4.5	70
20	Socioâ€economic status in childhood and later alcohol use: a systematic review*. Addiction, 2007, 102, 1546-1563.	3.3	69
21	Clinical effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: the CoBalT randomised controlled trial. Health Technology Assessment, 2014, 18, 1-167, vii-viii.	2.8	69
22	Physical activity and depression in adolescents: cross-sectional findings from the ALSPAC cohort. Social Psychiatry and Psychiatric Epidemiology, 2012, 47, 1023-1033.	3.1	62
23	Physical Activity and Common Mental Disorder: Results from the Caerphilly Study. American Journal of Epidemiology, 2007, 165, 946-954.	3.4	55
24	Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial. British Journal of Psychiatry, 2011, 198, 464-471.	2.8	55
25	Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. Psychopharmacology, 2014, 231, 2921-2931.	3.1	55
26	Psychological therapies for treatment-resistant depression in adults. The Cochrane Library, 2018, 2018, CD010558.	2.8	54
27	How much change is enough? Evidence from a longitudinal study on depression in UK primary care. Psychological Medicine, 2022, 52, 1875-1882.	4.5	51
28	No pain, no gain: Depressed clients' experiences of cognitive behavioural therapy. British Journal of Clinical Psychology, 2013, 52, 347-364.	3.5	48
29	Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). BMJ: British Medical Journal, 2018, 363, k4218.	2.3	44
30	Usefulness of PHQ-9 in primary care to determine meaningful symptoms of low mood: a qualitative study. British Journal of General Practice, 2016, 66, e78-e84.	1.4	33
31	Cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment resistant depression in primary care: The CoBalT randomised controlled trial protocol. Contemporary Clinical Trials, 2012, 33, 312-319.	1.8	32
32	Exploring patients' reasons for declining contact in a cognitive behavioural therapy randomised controlled trial in primary care. British Journal of General Practice, 2012, 62, e371-e377.	1.4	30
33	Pharmacological interventions for treatment-resistant depression in adults. The Cochrane Library, 2019, 12, CD010557.	2.8	30
34	Longitudinal Associations between Adolescent Psychotic Experiences and Depressive Symptoms. PLoS ONE, 2014, 9, e105758.	2.5	30
35	Socioeconomic Indicators of Treatment Prognosis for Adults With Depression. JAMA Psychiatry, 2022, 79, 406.	11.0	30
36	Effective dose 50 method as the minimal clinically important difference: Evidence from depression trials. Journal of Clinical Epidemiology, 2021, 137, 200-208.	5.0	29

#	Article	IF	CITATIONS
37	A comparison of four different approaches to measuring health utility in depressed patients. Health and Quality of Life Outcomes, 2013, 11, 81.	2.4	28
38	The contribution of depressive †disorder characteristics†to determinations of prognosis for adults with depression: an individual patient data meta-analysis. Psychological Medicine, 2021, 51, 1068-1081.	4.5	28
39	Detecting Heterogeneity of Intervention Effects Using Analysis and Meta-analysis of Differences in Variance Between Trial Arms. Epidemiology, 2021, 32, 846-854.	2.7	28
40	Cost-effectiveness of cognitive–behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: economic evaluation of the CoBalT Trial. British Journal of Psychiatry, 2014, 204, 69-76.	2.8	27
41	A Randomized Controlled Trial of Cognitive Behavioural Therapy as an Adjunct to Pharmacotherapy in Primary Care Based Patients with Treatment Resistant Depression: A Pilot Study. Behavioural and Cognitive Psychotherapy, 2008, 36, 21-33.	1.2	24
42	GENetic and clinical Predictors Of treatment response in Depression: the GenPod randomised trial protocol. Trials, 2008, 9, 29.	1.6	23
43	Severity of depression and response to antidepressants: GENPOD randomised controlled trial. British Journal of Psychiatry, 2012, 200, 130-136.	2.8	23
44	Management of treatment-resistant depression in primary care: a mixed-methods study. British Journal of General Practice, 2018, 68, e673-e681.	1.4	23
45	Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT. Health Technology Assessment, 2018, 22, 1-136.	2.8	21
46	The feasibility of low-intensity psychological therapy for depression co-occurring with autism in adults: The Autism Depression Trial (ADEPT) $\hat{a} \in \hat{a}$ a pilot randomised controlled trial. Autism, 2020, 24, 1360-1372.	4.1	18
47	Is social support preâ€treatment associated with prognosis for adults with depression in primary care?. Acta Psychiatrica Scandinavica, 2021, 143, 392-405.	4.5	17
48	Moderators of response to cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care. Journal of Affective Disorders, 2015, 174, 272-280.	4.1	16
49	Why do GPs exclude patients from participating in research? An exploration of adherence to and divergence from trial criteria. Family Practice, 2014, 31, 364-370.	1.9	15
50	A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial. Trials, 2017, 18, 496.	1.6	15
51	Design Considerations for the Integrated Delivery of Cognitive Behavioral Therapy for Depression: User-Centered Design Study. JMIR Mental Health, 2020, 7, e15972.	3.3	15
52	Trends in the recording of anxiety in UK primary care: a multi-method approach. Social Psychiatry and Psychiatric Epidemiology, 2022, 57, 375-386.	3.1	13
53	Integrating the Digital and the Traditional to Deliver Therapy for Depression. , 2020, , .		13
54	Protocol for a feasibility study and randomised pilot trial of a low-intensity psychological intervention for depression in adults with autism: the Autism Depression Trial (ADEPT). BMJ Open, 2017, 7, e019545.	1.9	12

#	Article	IF	Citations
55	Variation in recognition of happy and sad facial expressions and self-reported depressive symptom severity: A prospective cohort study. Journal of Affective Disorders, 2019, 257, 461-469.	4.1	12
56	A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRession): study protocol for a randomised controlled trial. Trials, 2019, 20, 319.	1.6	12
57	Personality difficulties and response to community-based psychological treatment for anxiety and depression. Journal of Affective Disorders, 2021, 279, 266-273.	4.1	12
58	Guided self-help for depression in autistic adults: the ADEPT feasibility RCT. Health Technology Assessment, 2019, 23, 1-94.	2.8	12
59	Individuals' Long Term Use of Cognitive Behavioural Skills to Manage their Depression: A Qualitative Study. Behavioural and Cognitive Psychotherapy, 2017, 45, 46-57.	1.2	11
60	Referenceâ€based multiple imputation for missing data sensitivity analyses in trialâ€based costâ€effectiveness analysis. Health Economics (United Kingdom), 2020, 29, 171-184.	1.7	11
61	Patients' experiences of participating in a large-scale trial of cognitive behavioural therapy for depression: a mixed methods study. Family Practice, 2013, 30, 705-711.	1.9	10
62	Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial. Trials, 2016, 17, 66.	1.6	10
63	A Patient Stratification Approach to Identifying the Likelihood of Continued Chronic Depression and Relapse Following Treatment for Depression. Journal of Personalized Medicine, 2021, 11, 1295.	2.5	10
64	Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT. Health Technology Assessment, 2021, 25, 1-62.	2.8	9
65	GPs' views and experiences of managing patients with personality disorder: a qualitative interview study. BMJ Open, 2019, 9, e026616.	1.9	8
66	An expert consensus on the most effective components of cognitive behavioural therapy for adults with depression: a modified Delphi study. Cognitive Behaviour Therapy, 2020, 49, 242-255.	3.5	8
67	PTSD as a mediator of the relationship between trauma and psychotic experiences. Psychological Medicine, 2022, 52, 2722-2730.	4.5	8
68	Identifying patients at risk of psychosis: a qualitative study of GP views in South West England. British Journal of General Practice, 2021, 71, e113-e120.	1.4	8
69	Cost-Effectiveness of Different Formats for Delivery of Cognitive Behavioral Therapy for Depression: A Systematic Review Based Economic Model. Value in Health, 2020, 23, 1662-1670.	0.3	7
70	Life events and treatment prognosis for depression: A systematic review and individual patient data meta-analysis. Journal of Affective Disorders, 2022, 299, 298-308.	4.1	7
71	Rise in prescribing for anxiety in UK primary care between 2003 and 2018: a population-based cohort study using Clinical Practice Research Datalink. British Journal of General Practice, 2022, 72, e511-e518.	1.4	7
72	Materials used to support cognitive behavioural therapy for depression: a survey of therapists' clinical practice and views. Cognitive Behaviour Therapy, 2019, 48, 463-481.	3.5	6

#	Article	IF	CITATIONS
73	GPs' and patients' views on the value of diagnosing anxiety disorders in primary care: a qualitative interview study. British Journal of General Practice, 2021, 71, e450-e457.	1.4	6
74	Antidepressant treatment with sertraline for adults with depressive symptoms in primary care: the PANDA research programme including RCT. Programme Grants for Applied Research, 2019, 7, 1-108.	1.0	6
75	Cost-Utility Analysis of Discontinuing Antidepressants in England Primary Care Patients Compared with Long-Term Maintenance: The ANTLER Study. Applied Health Economics and Health Policy, 2022, 20, 269-282.	2.1	6
76	Cognitive behavioural therapy for treatmentresistant depression – Authors' reply. Lancet, The, 2013, 381, 1814-1815.	13.7	4
77	Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial. Journal of Psychopharmacology, 2021, 35, 919-927.	4.0	4
78	Pharmacological interventions for treatment-resistant depression in adults. The Cochrane Library, 0,	2.8	3
79	Cost-Effectiveness of Sertraline in Primary Care According to Initial Severity and Duration of Depressive Symptoms: Findings from the PANDA RCT. PharmacoEconomics - Open, 2020, 4, 427-438.	1.8	3
80	Sensitivity to missing not at random dropout in clinical trials: Use and interpretation of the trimmed means estimator. Statistics in Medicine, 2022, 41, 1462-1481.	1.6	3
81	Are multiple physical symptoms a poor prognostic factor or just a marker of depression severity? Secondary analysis of the GenPod trial. Journal of Affective Disorders, 2014, 163, 40-46.	4.1	2
82	Feasibility study of eye movement desensitisation and reprocessing (EMDR) in people with an at-risk mental state (ARMS) for psychosis: study protocol. BMJ Open, 2020, 10, e038620.	1.9	2
83	Does anxiety moderate the effectiveness of mirtazapine in patients with treatment-resistant depression? A secondary analysis of the MIR trial. Journal of Psychopharmacology, 2020, 34, 1342-1349.	4.0	2
84	Republished research: Facilitated physical activity as a treatment for depressed adults: randomised controlled trial:. British Journal of Sports Medicine, 2013, 47, 629-629.	6.7	1
85	Conditional Beliefs of Primary-Care Patients with Treatment-Resistant Depression. Behavioural and Cognitive Psychotherapy, 2016, 44, 513-526.	1.2	O